

(21) Application No:	2001360.3	(51) INT CL:	C07K 14/725 (2006.01)A61K 38/17 (2006.01) A61K 38/48 (2006.01)A61K 39/395 (2006.01) A61K 39/44 (2006.01)C07K 14/47 (2006.01) C07K 16/18 (2006.01)C07K 16/32 (2006.01) C07K 16/44 (2006.01)C07K 16/46 (2006.01)
(22) Date of Filing:	11.12.2019	(56) Documents Cited:	WO 2011/163412 A1WO 2005/063815 A2 US 20180271910 A1US 20170209549 A1 US 20160333082 A1US 20150182588 A1 US 20130078245 A1US 20050175608 A1 US 20040180046 A1
Date Lodged:	31.01.2020	(58) Field of Search:	INT CL A61K, C07K, C12N Other: PatSeer (US, EP, WO, JP, DE, GB, CN, FR, KR ,ES, AU, IN, CA, INPADOC Data); Google; Google Scholar; EBSCO; NCBI; EMBL; Lens.org
(30) Priority Data:	(31) 62778014(32) 11.12.2018(33) US		
(86) International Application Data:	PCT/US2019/065741 En 11.12.2019		
(87) International Publication Data:	WO2020/123662 En 18.06.2020		
(71) Applicant(s):	AdMIRx Inc. 400 Technology Square, Cambridge, Massachusetts, 02139, United States of America		
(72) Inventor(s):	Michael Steven Curtis Michael Storek Shelia Marie Violette Susan L Kalled Kelly C Fahnoe Cheng Ran Huang Ellen Garber Stark Frederick Robbins Taylor Justin Andrew Caravella Vernon Michael Holers		
(74) Agent and/or Address for Service:	Avidity IP Broers Building, Hauser Forum, 21 J J Thomson Ave, CAMBRIDGE, Cambridgeshire, CB3 0FA, United Kingdom		

(54) Title of the Invention: **Fusion protein constructs for complement associated disease**
Abstract Title: **Fusion protein constructs for complement associated disease**

(57) Provided herein are fusion protein constructs that can bind a complement-associated antigen, comprising a targeting moiety and a complement modulator protein, or a fragment thereof or a variant thereof. The targeting moiety is an antibody or an antigen binding fragment thereof, in some examples. Further provided are methods of using the fusion protein constructs, for example, in treating complement mediation conditions.




FIG. 14